BioAtla, Inc. (NASDAQ:BCAB) Shares Sold by SC&H Financial Advisors Inc.

SC&H Financial Advisors Inc. lowered its position in BioAtla, Inc. (NASDAQ:BCAB) by 7.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 65,519 shares of the company’s stock after selling 5,606 shares during the quarter. SC&H Financial Advisors Inc. owned about 0.14% of BioAtla worth $161,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in BCAB. Barclays PLC bought a new position in BioAtla in the 2nd quarter worth $27,000. SG Americas Securities LLC acquired a new stake in shares of BioAtla during the 3rd quarter valued at about $37,000. Panagora Asset Management Inc. bought a new position in BioAtla during the 3rd quarter valued at about $90,000. Formidable Asset Management LLC lifted its holdings in BioAtla by 79.0% during the 3rd quarter. Formidable Asset Management LLC now owns 162,794 shares of the company’s stock valued at $277,000 after purchasing an additional 71,859 shares during the last quarter. Finally, Sectoral Asset Management Inc. lifted its holdings in BioAtla by 26.9% during the 3rd quarter. Sectoral Asset Management Inc. now owns 706,062 shares of the company’s stock valued at $1,200,000 after purchasing an additional 149,544 shares during the last quarter. 77.23% of the stock is currently owned by institutional investors.

BioAtla Trading Up 3.2 %

Shares of BCAB stock traded up $0.07 on Tuesday, hitting $2.25. The company’s stock had a trading volume of 245,566 shares, compared to its average volume of 506,003. The stock’s 50 day moving average is $2.80 and its 200-day moving average is $2.25. BioAtla, Inc. has a fifty-two week low of $1.24 and a fifty-two week high of $4.07.

BioAtla (NASDAQ:BCAB) last posted its quarterly earnings results on Tuesday, March 26th. The company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.12. As a group, sell-side analysts anticipate that BioAtla, Inc. will post -1.93 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on BCAB shares. HC Wainwright dropped their price target on shares of BioAtla from $10.00 to $7.00 and set a “buy” rating for the company in a research note on Wednesday, March 27th. JMP Securities reiterated a “market outperform” rating and issued a $12.00 price target on shares of BioAtla in a report on Thursday, March 28th.

BioAtla Company Profile

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.